Instrument Inactif

Communiqués Advanced Cell Technology, Inc. OTC Bulletin Board

Actions

ACTC

US00752K2042

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

Communiqués

10/02/16	Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries	PR
22/01/16	Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics	PR
28/12/15	Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells	BU
03/12/15	Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis	BU
24/11/15	Ocata Therapeutics : Harwood Feffer LLP : Announces Investigation of Ocata Therapeutics, Inc.	PR
12/11/15	Ocata Therapeutics : SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Therapeutics, Inc. (OCAT) Over the Proposed Sale of the Company to Astellas Pharma Inc.	BU
11/11/15	OCATA THERAPEUTICS : Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.	BU
11/11/15	Ocata Therapeutics : Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc. -- OCAT	PR
10/11/15	Ocata Therapeutics : Brower Piven Commences An Investigation Into The Proposed Sale Of Ocata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
10/11/15	Ocata Therapeutics : Levi & Korsinsky, LLP Notifies Shareholders of Ocata Therapeutics, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Astellas Pharma Inc.	BU
10/11/15	Ocata Therapeutics : Astellas to Acquire Ocata Therapeutics	PR
06/11/15	Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015	BU
23/09/15	Ocata Therapeutics : to Present at Ladenburg Thalmann 2015 Healthcare Conference	BU
22/09/15	Ocata Therapeutics : Canine Patients Treated with Ocata’s Hemangio-derived Mesenchymal Cells (HMC™) Achieve Remission in a Model of Crohn’s Disease	BU
08/09/15	Ocata Therapeutics : First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD	BU
03/09/15	Ocata Therapeutics : Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer	BU
01/09/15	Ocata Therapeutics : Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa	BU
31/08/15	Ocata Therapeutics : Appoints Dr. Brian Levy to its Board of Directors	BU
24/08/15	Ocata Therapeutics : Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis	BU
19/08/15	Ocata Therapeutics : Secures $10 Million in Debt Financing	BU
06/08/15	Ocata Therapeutics : Provides Corporate Update for the Second Quarter of 2015	BU
31/07/15	Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015	BU
15/07/15	Ocata Therapeutics : Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases	BU
14/07/15	Ocata Therapeutics : Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus	BU
01/07/15	Ocata Therapeutics : to Present at the Cantor Fitzgerald Inaugural Healthcare Conference	BU